



A Progression-free Survival among All Patients**No. at Risk**

Ibrutinib-rituximab	354	339	298	148	16
Chemoimmunotherapy	175	147	112	50	0

B Progression-free Survival among Patients with IGHV-Unmutated CLL**No. at Risk**

Ibrutinib-rituximab	210	203	177	90	12
Chemoimmunotherapy	71	64	43	14	0

C Subgroup Analysis